- Home
- JFU vs SPRB Comparison
JFU vs SPRB Comparison
Compare JFU & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- SPRB
- Stock Information
- Founded
- JFU 2006
- SPRB 2014
- Country
- JFU China
- SPRB United States
- Employees
- JFU N/A
- SPRB N/A
- Industry
- JFU Finance: Consumer Services
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- JFU Finance
- SPRB Health Care
- Exchange
- JFU Nasdaq
- SPRB Nasdaq
- Market Cap
- JFU 17.8M
- SPRB 15.7M
- IPO Year
- JFU 2019
- SPRB 2020
- Fundamental
- Price
- JFU $1.37
- SPRB $0.33
- Analyst Decision
- JFU
- SPRB Hold
- Analyst Count
- JFU 0
- SPRB 7
- Target Price
- JFU N/A
- SPRB $2.17
- AVG Volume (30 Days)
- JFU 6.8K
- SPRB 300.3K
- Earning Date
- JFU 01-01-0001
- SPRB 03-21-2025
- Dividend Yield
- JFU N/A
- SPRB N/A
- EPS Growth
- JFU N/A
- SPRB N/A
- EPS
- JFU 0.09
- SPRB N/A
- Revenue
- JFU $40,614,155.00
- SPRB $7,101,000.00
- Revenue This Year
- JFU N/A
- SPRB N/A
- Revenue Next Year
- JFU N/A
- SPRB N/A
- P/E Ratio
- JFU $15.56
- SPRB N/A
- Revenue Growth
- JFU N/A
- SPRB N/A
- 52 Week Low
- JFU $1.13
- SPRB $0.33
- 52 Week High
- JFU $3.75
- SPRB $1.29
- Technical
- Relative Strength Index (RSI)
- JFU 39.00
- SPRB 27.09
- Support Level
- JFU $1.38
- SPRB $0.34
- Resistance Level
- JFU $1.56
- SPRB $0.36
- Average True Range (ATR)
- JFU 0.08
- SPRB 0.03
- MACD
- JFU -0.02
- SPRB -0.01
- Stochastic Oscillator
- JFU 0.00
- SPRB 2.70
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).